Payment overview · 2025
General Payments
$462.52
17 reported records · 13 companies
Healthcare provider profile · identity verified
Steven M Rosenberg, DO
Allopathic & Osteopathic Physicians|Family Medicine · FEASTERVILLE, PA · NPI 1083610471
Verified facts
What the public records show
CMS Open Payments records show Steven M Rosenberg, DO received $462.52 in general payments during 2025 across 17 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $124.86 | 27.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.37 | 8.7% | 2 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.14 | 8.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.83 | 8.4% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $37.13 | 8.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.09 | 6.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $30.66 | 6.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.83 | 5.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.39 | 5.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.29 | 4.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.16 | 4.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.22 | 3.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.55 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $462.52 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $124.86 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $37.13 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.09 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $30.66 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 106 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 24 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 435 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 399 | 114 |
| Lorazepam | Lorazepam | 369 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 99 |
| Lisinopril | Lisinopril | 305 | 98 |
| Losartan Potassium | Losartan Potassium | 239 | 70 |
| Alprazolam | Alprazolam | 230 | 32 |
| Omeprazole | Omeprazole | 225 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 70 |
| Gabapentin | Gabapentin | 205 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 186 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 50 |
| Tramadol Hcl | Tramadol Hcl | 163 | 30 |
| Furosemide | Furosemide | 157 | 46 |
| Metformin Hcl | Metformin Hcl | 151 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 26 |
| Sertraline Hcl | Sertraline Hcl | 137 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 48 |
| Ezetimibe | Ezetimibe | 123 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 41 |
| Methylprednisolone | Methylprednisolone | 109 | 69 |
| Ozempic | Semaglutide | 109 | 17 |
| Eliquis | Apixaban | 108 | 24 |
| Simvastatin | Simvastatin | 108 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 46 |
| Jardiance | Empagliflozin | 106 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 100 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 30 |
| Glimepiride | Glimepiride | 97 | 27 |
| Clonazepam | Clonazepam | 96 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 28 |
| Trazodone Hcl | Trazodone Hcl | 94 | 31 |
| Meloxicam | Meloxicam | 93 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 21 |
| Atenolol | Atenolol | 86 | 25 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 77 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 21 |
| Allopurinol | Allopurinol | 73 | 27 |
| Azithromycin | Azithromycin | 71 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 14 |
| Celecoxib | Celecoxib | 61 | 18 |
| Alendronate Sodium | Alendronate Sodium | 58 | 20 |
| Carvedilol | Carvedilol | 57 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 35 |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 47 | 19 |
| Famotidine | Famotidine | 45 | 17 |
| Synthroid | Levothyroxine Sodium | 44 | 11 |
| Metformin Hcl Er | Metformin Hcl | 41 | 15 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 11 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 37 | 25 |
| Bupropion Xl | Bupropion Hcl | 37 | 13 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 13 |
| Pitavastatin Calcium | Pitavastatin Calcium | 36 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Montelukast Sodium | Montelukast Sodium | 35 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Finasteride | Finasteride | 32 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 32 | suppressed |
| Prednisone | Prednisone | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 13 |
| Gemtesa | Vibegron | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 12 |
| Testosterone | Testosterone | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Fluvastatin Er | Fluvastatin Sodium | 13 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $462.52 · 17 records | SANOFI-AVENTIS U.S. LLC | AREXVY, Auvelity, CAPVAXIVE, DUPIXENT, GARDASIL 9, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, TZIELD, VRAYLAR, WELLBUTRIN, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error